COCRYSTAL PHARMA, INC. Operating Lease Cost
COCRYSTAL PHARMA, INC. (COCP) reported Operating Lease Cost of $410.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-03-31
- COCRYSTAL PHARMA, INC. operating lease, cost for fiscal 2025 was $410.00K, a 4.33% increase from fiscal 2024.
- COCRYSTAL PHARMA, INC. operating lease, cost for fiscal 2024 was $393.00K, a 68.67% increase from fiscal 2023.
- COCRYSTAL PHARMA, INC. operating lease, cost for fiscal 2023 was $233.00K, a 0.00% change from fiscal 2022.
- COCRYSTAL PHARMA, INC. operating lease, cost for fiscal 2022 was $233.00K, a 1.30% increase from fiscal 2021.
| Period end | Operating Lease, Cost 12 month |
|---|---|
| 2025-12-31 | $410.00K 10-K · filed 2026-03-31 |
| 2024-12-31 | $393.00K 10-K · filed 2026-03-31 |
| 2023-12-31 | $233.00K 10-K · filed 2025-03-31 |
| 2022-12-31 | $233.00K 10-K · filed 2023-03-29 |
| 2021-12-31 | $230.00K 10-K · filed 2022-03-23 |
| 2020-12-31 | $228.00K 10-K · filed 2021-03-17 |
| 2019-12-31 | $214.00K 10-K · filed 2020-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |